Moreover, the 36-month beta value for TRIB is 1.24. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TRIB is 11.69M and currently, short sellers hold a 1.82% of that float. On September 19, 2024, TRIB’s average trading volume was 1.28M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TRIB) stock’s latest price update
The stock price of Trinity Biotech Plc ADR (NASDAQ: TRIB) has plunged by -6.25 when compared to previous closing price of 1.60, but the company has seen a -7.41% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-09-18 that DUBLIN, Sept. 18, 2024 (GLOBE NEWSWIRE) — Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today provided an update on its development and global launch plans for its next generation Continuous Glucose Monitoring (“CGM”) technology. CGMs are small patch-like wearable medical devices that use biosensor wires under the skin to measure glucose in real-time. These devices are increasingly popular in diabetes management and health monitoring.
TRIB’s Market Performance
Trinity Biotech Plc ADR (TRIB) has seen a -7.41% fall in stock performance for the week, with a -37.16% decline in the past month and a -42.08% plunge in the past quarter. The volatility ratio for the week is 5.69%, and the volatility levels for the past 30 days are at 9.82% for TRIB. The simple moving average for the last 20 days is -21.25% for TRIB stock, with a simple moving average of -33.02% for the last 200 days.
Analysts’ Opinion of TRIB
ROTH Capital gave a rating of “Buy” to TRIB, setting the target price at $20 in the report published on July 29th of the previous year.
TRIB Trading at -38.79% from the 50-Day Moving Average
After a stumble in the market that brought TRIB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.03% of loss for the given period.
Volatility was left at 9.82%, however, over the last 30 days, the volatility rate increased by 5.69%, as shares sank -36.17% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -38.27% lower at present.
During the last 5 trading sessions, TRIB fell by -7.41%, which changed the moving average for the period of 200-days by -37.11% in comparison to the 20-day moving average, which settled at $1.8623. In addition, Trinity Biotech Plc ADR saw -30.07% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for TRIB
Current profitability levels for the company are sitting at:
- -0.22 for the present operating margin
- 0.32 for the gross margin
The net margin for Trinity Biotech Plc ADR stands at -0.38. The total capital return value is set at -0.19. Equity return is now at value -1967.61, with -26.81 for asset returns.
Based on Trinity Biotech Plc ADR (TRIB), the company’s capital structure generated 1.55 points at debt to capital in total, while cash flow to debt ratio is standing at -0.16. The debt to equity ratio resting at -2.83. The interest coverage ratio of the stock is -1.85.
Currently, EBITDA for the company is -13.48 million with net debt to EBITDA at -8.14. When we switch over and look at the enterprise to sales, we see a ratio of 1.81. The receivables turnover for the company is 3.31for trailing twelve months and the total asset turnover is 0.62. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.78.
Conclusion
To wrap up, the performance of Trinity Biotech Plc ADR (TRIB) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
